Literature DB >> 31264794

Synthesis of Substituted 5'-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73.

Rayane Ghoteimi1, Van Tai Nguyen1, Rahila Rahimova2, Felix Grosjean1, Emeline Cros-Perrial3, Jean-Pierre Uttaro1, Christophe Mathé1, Laurent Chaloin2, Lars Petter Jordheim3, Suzanne Peyrottes1.   

Abstract

Derivatives of 5'-aminoadenosine containing methyl carboxylate, methyl phosphonate, gem-bisphosphonate, bis(methylphosphonate), and α-carboxylmethylphosphonate or phosphonoacetate moieties were synthesized from key intermediate 5'-aminonucleoside. These nucleotide analogues were envisaged as 5'-mono- or diphosphate nucleoside mimics. All compounds were evaluated for CD73 inhibition in a cell-based assay (MDA-MB-231) and toward the purified recombinant protein. Most of them failed to reach significant inhibition of AMP hydrolysis by CD73 at 100 μm. Among the new compounds, the most interesting candidates, 5 (5'-deoxy-5'-N-phosphonomethyladenosine) and 7 (5'-deoxy-5'-N-(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 μm, respectively. Molecular modeling partially explains this lack of activity, as the initially predicted docking scores had been encouraging, especially for compound 9.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  5′-ectonucleotidase; cancer; enzyme inhibitors; immunotherapy; nucleotide analogues

Year:  2019        PMID: 31264794     DOI: 10.1002/cmdc.201900348

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  3 in total

1.  Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors.

Authors:  Mirko Scortichini; Riham Mohammed Idris; Susanne Moschütz; Antje Keim; Veronica Salmaso; Clemens Dobelmann; Paola Oliva; Karolina Losenkova; Heikki Irjala; Samuli Vaittinen; Jouko Sandholm; Gennady G Yegutkin; Norbert Sträter; Anna Junker; Christa E Müller; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2022-01-26       Impact factor: 7.446

2.  CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?

Authors:  Ana Maria Oliveira Battastini; Fabricio Figueiró; Daniela Bitencourt Rosa Leal; Pedro Henrique Doleski; Maria Rosa Chitolina Schetinger
Journal:  Front Pharmacol       Date:  2021-03-11       Impact factor: 5.810

3.  Transcriptional and Metabolic Investigation in 5'-Nucleotidase Deficient Cancer Cell Lines.

Authors:  Octavia Cadassou; Prescillia Forey; Christelle Machon; Edoardo Petrotto; Kamel Chettab; Maria Grazia Tozzi; Jérôme Guitton; Charles Dumontet; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.